“…Transverse melanonychia has occurred in conjunction with use of the following: electron beam therapy [20], conventional radiographic therapy to treat hand dermatitis (used in the 1950s and 1960s) [21, 22], psoralen with ultraviolet A (PUVA) [23–26], infliximab [27], zidovudine [28], prolonged antimalarial therapy with amodiaquine, chloroquine, mepacrine, or quinacrine [2, 26, 28], and chemotherapy with agents such as doxorubicin, bleomycin, cyclophosphamide, daunorubicin, dacarbazine, 5-fluorouracil, methotrexate [20], and hydroxyurea [26, 29, 30]. Transverse melanonychia associated with electron beam therapy and PUVA is benign and typically resolves with the cessation of treatment [20, 23, 26]. Interestingly, for antimalarials amodiaquine, chloroquine, and mepacrine, transverse melanonychia may be attributable to either melanin production or more commonly ferric dyschromia [2].…”